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Itch is described as an unpleasant sensation that elicits the desire to scratch, which results in the removal of the
irritant from the skin. The cough reflex also results from irritation, with the purpose of removing said irritant from
the airway. Could cough then be similar to itch? Anatomically, both pathways are mediated by small-diameter
sensory fibers. These cough and itch sensory fibers release neuropeptides upon activation, which leads to
inflammation of the nerves. Both cough and itch also involve mast cells and their mediators, which are released
upon degranulation. This common inflammation and interaction with mast cells are involved in the development
of chronic conditions of itch and cough. In this review, we examine the anatomy and molecular mechanisms of
itch and compare them to known mechanisms for cough. Highlighting the common aspects of itch and cough
could lead to new thoughts and perspectives in both fields.
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Over 350 years ago, the German physician Samuel
Haffenreffer defined itch, or pruritus, as an “unpleasant
sensation that elicits the desire or reflex to scratch.”
Why is such an unpleasant sensation needed? Itch
causes the protective mechanism of scratching. The
physical act of scratching dislodges the irritant, such as
an insect or poisonous plant, from the skin. Therefore
itch results in the removal of a harmful stimulus.
Scratching may not just be protective though. The actual
act of scratching can result in mechanical pain, which
helps to suppress the unpleasant itchy sensation [1,2].
Therefore scratching can both help remove an irritant
and try to suppress the itch resulting from it.
Although the skin is the primary site for the generation
of itch, itchiness can also be felt in mucosal surfaces. So
perhaps itch is felt in the airway and since we cannot
scratch our airway, it is reasonable to think that the main
response to airway itch would be to cough. Coughing* Correspondence: plavink1@jhmi.edu; xdong2@jhmi.edu
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distribution, and reproduction in any mediumhelps to clear irritants and evoke itch-suppressing mech-
anical pain in the airway, similar to scratching itchy skin.
Coughing is most easily evoked from stimulation of the
larynx, trachea, and larger bronchi and many types of
stimuli can result in cough, not just itch [3]. The cough
reflex results in the removal of foreign material from the
large bronchi with successive coughs forcing the foreign
material or secretion through the smaller bronchi to-
wards the trachea so the irritants can be expelled [4,5].
In this review, we will talk about the mechanisms of itch
and cough and the similarities found between the path-
ways. The parallels between itch and cough can perhaps
lead to new perspectives and ideas in ways to test the re-
spective pathways and how they may possibly work.Review
Primary sensory fibers of itch and cough pathways
Before looking at the specifics of a sensory system, we
should first look at the basic anatomy that transmits the
sensory information. Figure 1 illustrates sensory fibers
that are primarily responsible for itch and cough. Pri-
mary sensory neurons in dorsal root ganglia (DRG) play
an essential role in generating itch by detecting itch
stimuli through their peripheral axons in the skin and
sending signals to the spinal cord via their central axons
[6]. In the cough pathway, the cough sensory afferententral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Primary sensory neurons of itch and cough. A. Itch is primarily sensed through the epithelium by unmyelinated C-fibers, whose cell
bodies are in the dorsal root ganglion. Degranulation of mast cells release inflammatory mediators that can activate C-fibers, which secrete
neuropeptides, such as Substance P. Secretion of Substance P results in inflammation and vasodilatation, which sensitizes nerves. B. Cough results
from activation of myelinated cough receptors and unmyelinated C-fibers, whose cell bodies are in the jugular and nodose ganglia. Extensive
C-fiber endings are found under the airway epithelium while cough receptors endings terminate in the mucosa between the epithelium and
smooth muscle. Degranulated mast cells release mediators that activate C-fibers, causing release of Substance P. Substance P release results in
inflammation, vasodilatation and sensitization of nerves.
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their cell bodies located in the vagal nodose or jugular
ganglia [4]. The nodose ganglia are embryologically de-
rived from the epibranchial placodes while the jugular
ganglia originate from the neural crest [7]. Interestingly,
the DRG sensory neurons also originate from the neural
crest [8]. Sensory neurons that play a role in itch or
cough can be classified into two distinct fibers, the thinly
myelinated Aδ-fiber and the unmyelinated C-fiber.
Myelinated Aδ-fibers
Itch In early investigations into itch, it was suggested
that there was two subjective components to itch. First a
‘pricking’ itch was felt, followed by a ‘burning’ itch. The
‘pricking’ itch was sensed via the myelinated sensory fi-
bers and abolished when these myelinated fibers were
blocked [9]. It has been shown in studies involving the
known pruritogen cowhage (Mucuna pruriens), that
mechanosensitive Aδ-fibers play a role in itch. Cowhage
causes intense itching when injected into the skin [10].
Psychophysical human studies show decreased itch from
cowhage upon blocking of myelinated A fibers. In mon-
keys, cowhage activates mechanosensitive A fibers while
some mechanoinsensitive A fibers are activated by an-
other pruritogen, histamine [11].
Cough Myelinated Aδ-fibers play a role in the gener-
ation of cough. The Aδ-fibers are responsible for the
violent, sudden cough that occurs upon aspiration [12].
These myelinated vagal afferent cough fibers are sensi-
tive to acid and mechanical stimulation but are relatively
insensitive to capsaicin and the effects of anesthesia [13].
In dogs, when myelinated nerve conduction is blocked
by vagal cooling, mechanically and chemically stimulatedcough is inhibited [14]. Single fiber vagal recordings of
afferent Aδ-fibers in the guinea pig trachea activate upon
exposure to known cough-evoking hypotonic, hyper-
tonic, and low-chloride stimuli [15]. Vagal Aδ-fibers also
show sensitivity to very low levels of touch stimulus,
which can trigger cough [16].
Different types of Aδ-fibers are involved in the regula-
tion of breathing and cough. These different myelinated
vagal sensory fibers include rapidly adapting receptors
(RARs), slowly adapting receptors (SARs) and the cough
receptors. The RARs and SARs are differentiated on
their ability to adapt to lung inflation, either rapidly or
slowly [17-19]. RARs and SARs are thought to play a
modulatory, synergistic role in the cough reflex but are
not responsible for initiating cough [13,20]. The myelin-
ated vagal fiber thought to be responsible for initiating
cough is the touch sensitive Aδ-fiber or cough receptor.
The cough receptor cell bodies are mostly located in the
nodose ganglia with axons terminating in a circumferen-
tial pattern between the epithelium and smooth muscle
in the mucosa of the guinea pig trachea [21]. The cough
receptors are very sensitive to punctate mechanical stim-
uli and changes in pH in conscious and anaesthetized
animals [22]. Up till recently, the cough receptor was in-
cluded in the RAR fibers, until Canning et al. distin-
guished this subset in their 2004 paper. Cough receptors
have several unique qualities that discriminate them
from being classified as RARs or SARs. Cough receptors
do not show a response to changes in lung volume like
RARs and SARs and are primarily located in the
extrapulmonary airways, rather than the intrapulmonary
airways [22]. These afferent myelinated fibers project to
the trachea via the recurrent laryngeal nerves and when
these nerves are cut, coughing is abolished [22]. The
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3–5 m/s and lack TRPV1 receptors, which is why they
are relatively insensitive to capsaicin [22,23].
The role of myelinated fibers in cough is much more
defined and explored when compared to myelinated fi-
bers’ role in itch. What is interesting in both is that
these myelinated fibers are not solely responsible for
the genesis of itch or cough. The myelinated A-fibers
interact with unmyelinated C-fibers to respond to irri-
tating stimuli, resulting in itch or cough. In the skin,
cowhage causes itch through activation of both mye-
linated and unmyelinated fibers [11,24]. In the airway,
activation of C-fibers results in many of the same re-
flexes (cough, bronchoconstriction) as activation of
myelinated fibers, so the reflexes are likely a result of
both types of sensory fibers [25]. In both itch and
cough, C-fibers play a role in setting the threshold,
controlling the sensitivity of the system.
C fibers
Itch Itch is primarily mediated by slower conducting
C-fibers innervating the dorsal horn of the spinal cord.
Early itch studies used spicules of cowhage to show
that the strongest itch is felt in the dermo-epidermal
juncture area, the area where unmyelinated sensory fi-
bers innervate [10,26]. Five percent of the C-fibers in-
nervating the skin react to puritogenic application,
with distinct populations of C-fibers corresponding to
itch in individual nerve C-fiber recordings in humans
[24,27]. Itch sensing C-fibers slowly conduct action po-
tentials (0.5 m/s) and innervate large territories of skin
[27]. When C-fibers are desensitized with pretreatment
of capsaicin, itch is greatly reduced or blocked [28].
However, not all C fibers respond equally to all
pruritogens. C-fibers can be divided into subcategories
according to their response to various stimuli and
these subcategories respond differently to different
pruritic stimuli. C-fibers classified as mechanical and
heat responsive (CMH) have been shown to respond
to cowhage and histamine [29]. Mechanically-insensitive
C-fibers that respond to histamine (CMiHis+) have a
preferential, not exclusive, activation to pruritic sub-
stances such as histamine and prostaglandin E(2) (PGE2)
and substances that activate more of these specific
CMiHis+ fibers are considered more potent pruritic
agents [19]. Microneurography recordings of C-fibers
in human volunteers show that cowhage activates
mechanosensitive C-fibers while histamine activates
mechano-insensitive units. Capsaicin activates fibers in
both classes [24]. So cowhage induces itch through a dif-
ferent set of C-fibers than histaminergic itch. The acti-
vation of two different subsets of C-fibers shows that
there are multiple pathways for pruritus, changing
according to the stimulus.Cough C-fibers are also involved in the generation of
cough. It is thought that C-fibers are important to a sec-
ond type of cough, which is used to get rid of an itchy
feeling in one’s throat. This feeling is more typical of
chronic cough [12]. Cough is generated when vagal
C-fibers and myelinated cough receptors are activated
[20]. The C-fibers form a loose network in the airway mu-
cosa with branches found in deeper lung structures [7].
The majority of C-fibers innervating the airway arise from
the vagus nerve, however there is also some innervation
by spinal afferent C-fibers whose cell bodies are in the
DRG [30]. There are two sets of vagal C-fibers, the bron-
chial C-fibers which innervate the large airways and the
pulmonary C-fibers which innervate the smaller, peri-
pheral lung tissue [30]. Collectively these C-fibers are the
bronchopulmonary C-fibers and can be activated using a
variety of chemical stimuli, including capsaicin, bradykinin
and protons. Inhalation of these chemicals such as capsa-
icin in humans causes an itchy feeling in the airway and
evokes cough [12,20,31,32]. In single fiber recordings, all
vagal C-fibers tested respond to capsaicin and capsaicin-
sensitive C-fibers are found in both the nodose and jugu-
lar ganglion [7,16]. However, in dogs and rats, rapid shal-
low breathing is caused by C-fiber activation, but not
cough, showing that there can be species differences
[3,14,33]. In fact, C-fiber activation can inhibit mechani-
cally induced cough [14]. These inhibitory C-fibers are
thought to be the C-fibers with cell bodies in the nodose
ganglion. Indeed, activation of nodose C-fibers with ad-
enosine reduce citric acid evoked cough [20]. This implies
that the jugular ganglia C-fibers are the ones playing an
excitatory role in cough. The differences seen in C-fibers
originating from the nodose ganglia versus C-fibers origi-
nating from the jugular ganglia are evidence of a multi-
faceted cough reflex with many ways to fine-tune a re-
sponse. However, the fact that many C-fiber activators
cause cough in awake guinea pigs and humans, speaks to
their role in generating cough.
Anatomically, the chemosensitive C-fibers extend nu-
merous terminals superficially into the airway epithelium,
placing them in an ideal position to react to inhaled che-
mical irritants [34]. Labeling studies in guinea pigs show
C-fibers terminating underneath the airway epithelium,
with swelling suggestive of the presence of synaptic vesi-
cles filled with Substance P (SP), Calcitonin gene related
peptide (CGRP) and Neurokinin A [21]. When the fibers
innervating the tracheal epithelium are analyzed, nearly all
C-fibers have cell bodies in the jugular ganglion and 60%
are containing fibers [32,35]. These jugular C-fibers pro-
mote coughing [20]. No peptide positive fibers are found
in the nodose ganglion [32,36]. So within the C-fibers
there are two subsets, peptidergic (in jugular ganglion)
and non-peptidergic (in nodose ganglion) [37]. However,
the C-fibers that innervate the lungs (below the trachea)
Table 1 Activators and modulators of itch and cough
pathways
Agent Pathway Evoke Itch Evoke Cough
Bradykinin B1, B2 Weakly, modulator Yes, modulator
Capsaicin TRPV1 superficial application,
Yes, modulator
Yes
Oxidative TRPA1 Yes Yes, modulator
Cowhage PAR2, PAR4 Yes Yes
Histamine H1, H4 Yes, modulator Modulator
Proteases PAR1, PAR2, PAR4 Yes Modulator
Serotonin 5HT2, 5HT3 Yes Modulator
Substance P NK1, NK2 Yes Modulator
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the lungs found in the nodose ganglion [7].
Many argue that direct cough is caused by the touch
sensitive Aδ-fibers and that C-fibers cause cough by in-
direct mechanisms. This is shown by C-fiber evoked
cough’s sensitivity to anesthesia. Anaesthetized ani-
mals often do not cough upon application of C-fiber
stimulants but cough when awake. Stimulation of
bronchopulmonary C-fibers with chemical stimuli can
result in bronchoconstriction and mucous produc-
tion, both of which can cause cough [38]. Stimulated
C-fibers release which mediates nitric oxide and re-
sults in an increase in fluid in airways, activating
RARs and causing cough [39]. It was found that pre-
treatment with a C-fiber stimulant, while not evoking
cough alone, decreased the cough threshold for RAR
and cough receptor stimulation. Conversely, desensi-
tizing C-fibers with capsaicin application, led to a
decrease in coughing upon myelinated cough fiber
activation [40]. These findings suggest a synergistic
central interaction between C-fibers and myelinated
RARs and cough receptors.
With the knowledge that C-fibers are involved in both
itch and cough, it is likely that there are similarities to
be found in activation of these sensory neurons. Large
territories of innervation by C-fibers are seen in both the
skin and lung. The jugular ganglion is derived from the
neural crest, just like the dorsal root ganglion. With
similar embryonic starts, these fibers may share many
characteristics. Neural crest derived vagal nerves are
seen innervating the large extrapulmonary airways while
placodal nerves are seen innervating deeper lung tissue
leading to speculation that the more superficial neural
crest derived vagal nerves are responsible for reacting to
external environmental stimuli [7,37]. This parallels the
more superficial termination of C-fibers in the skin that
are thought to be responsible for itch [41].
Knowing that itch and cough are mediated by similar
sensory neurons, the specifics of activating these fibers
can be examined and compared. Two types of receptors
are activated on sensory fibers, ionotropic and metabo-
tropic. In both of these categories, itch and cough work
through the same receptors in multiple instances. Table 1
lists some of the known pruritic and tussive agents and
modulators as well as their pathways.
Ionotropic receptors of itch and cough
TRPV1
Itch The transient receptor potential, vanilloid 1 (TRPV1)
receptor is a membrane bound, ligand gated channel. It is
a six transmembrane spanning protein that undergoes a
conformational change upon binding of a ligand, allowing
cations into the nerve and resulting in activation of pri-
mary sensory neurons [42]. The role of TRPV1 has oftenbeen explored using one of its most famous ligands, cap-
saicin. If capsaicin is applied in a punctuate manner to the
epidermis, it causes itch [43]. TRPV1 are expressed on a
subset of C-fibers and repeated application of capsaicin
will desensitize these C-fibers. Desensitizing C-fibers help
reduce the itch induced by histamine [28]. When TRPV1
receptors were blocked by capsazepine, histamine evoked
currents were reduced in sensory neurons. Similarly, hista-
mine failed to activate TRPV1−/− neurons [44]. Therefore,
TRPV1 plays an important role in histamine-dependent
itch. Mice deficient in Pirt, a TRPV1 modulator, have de-
creased scratching in response to histamine, chloro-
quine, and ET-1, implicating TRPV1 as an important
component in multiple itch pathways [45].
While TRPV1 can be directly activated by capsaicin,
its main role is functioning downstream of many
pruritogens. Pruritogens activate G protein coupled re-
ceptors (GPCRs) that result in intracellular cascades
that can activate TRPV1 [44,46]. GPCR activation re-
sults in production of phospholipase C (PLC) beta3,
an intracellular mediator that activates TRPV1 upon
histamine application [44]. PLCbeta3 also mediates
serotonin-evoked itch [46]. TRPV1 can also be acti-
vated by diacylglycerol (DAG) which is produced when
PIP2 is hydrolyzed by PLC [46,47]. Expression of
TRPV1 and phosphorylated TRPV1 receptors increase
in atopic dermatitis (AD) mouse models lesions [48].
TRPV1 contributes to skin inflammation by causing
release which leads to upregulation of SP’s receptor,
neurokinin 1 (NK1). Increased levels of NK1 expression
is seen in lesions from AD models [48,49]. Blocking
TRPV1 stops the upregulation of NK1 receptors and de-
creases bouts of scratching [48].Cough TRPV1 is also thought to be a strong effector of
the cough reflex in response to many different stimuli
[50]. TRPV1 is found in both vagal ganglia as well as
throughout the airway [51,52]. Airway mucosal biopsies
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fivefold increase in TRPV1 expression [53].
Capsaicin is a commonly used tussive agent and
resiniferatoxin, a strong TRPV1 agonist, causes cough
by direct activation of TRPV1 [54]. PGE2 and bradyki-
nin, which are known to cause cough, depolarize vagal
sensory neurons through activation of TRPV1 [50].
Citric acid evoked cough works through activation of
TRPV1 and antagonizing the receptor with capsazepine
and ruthenium red reduces citric acid cough [55,56].
Anandamide has been shown to activate nodose gan-
glion cells and induce cough in guinea pigs through a
TRPV1-dependent mechanism [57].TRPA1
Itch TRPA1 is a strong noxious sensor due to reactive
cysteines that can form covalent bonds with multiple
chemical compounds [58,59]. TRPA1 has been shown to
be important to histamine-independent itch. The GPCRs
MrgprA3 and MrgprC11 are activated by chloroquine
and BAM8-22 respectively, both of which cause
scratching [60]. When TRPA1 is blocked or deleted, itch
caused by BAM and chloroquine is drastically reduced
[61]. This indicates TRPA1 is activated downstream by
MrgprA3 and MrgprC11. Whereas TRPV1 is activated
by G-alpha activating the PLC pathway, TRPA1 is
shown to interact with the G-Beta-Gamma subunit dir-
ectly [61]. It has been recently shown that oxidative
challenges (H2O2 injections) can cause scratching,
seemingly as a result of itch. The mechanism was
shown to be dependent on TRPA1, not TRPV1 [62].
This is important as oxidative stress is involved in dis-
eases causing chronic itch [63].Cough TRPA1 is found in TRPV1+ vagal sensory neurons
innervating the airway and accordingly, cinnamaldehyde
(TRPA1 agonist) stimulates capsaicin (TRVP1 agonist)
sensitive neurons [64]. Since TRPA1 is found in the air-
way and reacts to many chemicals, it is a good candidate
for an environmental sensor that can activate cough.
TRPA1 has been shown to be an oxidant sensor in mur-
ine airway neurons [65,66]. Indeed, multiple TRPA1 li-
gands are found to evoke cough in guinea pigs and
humans [67]. TRPA1 agonists stimulate jugular C-fibers
innervating the trachea and TRPA1 mediates irritation
induced by chemicals found in cigarette smoke and air
pollution (eg acrolein and crotonaldehyde) [68,69]. Inter-
estingly, TRPA1 has been shown to evoke cough inde-
pendent of TRPV1 as TRPV1 antagonists could not
prevent acrolein evoked cough. However, desensitization
of the C-fibers that contain both TRPA1 and TRPV1
did abolish TRPA1 cough [70].Inflammatory mediators
Activation of TRP channels leads to release of inflamma-
tory neuropeptides from C-fibers. These neuropeptides
include the tachykinins (Substance P, neurokinin A,
neurokinin B) and calcitonin gene related peptide
(CGRP) [71]. Other inflammatory chemicals, such as
bradykinin, may also be released. Neurogenic inflamma-
tion has been shown to play roles in both chronic itch
and chronic cough.
Substance P
Itch Application of SP to the skin in humans causes itch
which is prevented by antihistamines and so is thought
to be histamine dependent [72]. This collaborates with
the fact that depleting mast cells, a primary source of
histamine, with compound 48/80 decreased the itching,
wheal and flare response from SP intradermal injections
in human volunteers [73]. Substance P is thought to
mediate itch through activation of the neurokinin (NK)
receptors. After skin-scratching stimulation, NK1 is up-
regulated in the epidermal keratinocytes and Substance P
is depleted from sensory fibers, indicating secretion of SP
into the surrounding cells [74]. It was found that NK1 an-
tagonists inhibit scratching in a dermatitis model [75].
Clinically, patients with chronic pruritus have reduced
itching upon using a NK1 antagonist [76].
Cough Substance P results in plasma extravasation in
the airways, which can activate RARs [77]. In vivo, Sub-
stance P only causes weak and variable cough in guinea
pigs [78]. Furthermore, nodose neurons from healthy
guinea pigs show no reaction to Substance P application.
However, once inflammation is induced by antigen in-
halation, 80% of nodose neurons respond to Substance
P. Airway inflammation unmasks the Substance P re-
sponse that is shown to be mediated by NK2 receptors
[79]. Increased levels of Substance P are found in the
nasal epithelial cells of patients with cough hypersensi-
tivity and chronic cough. This correlates with increased
levels of nitrosative stress, which enhances Substance P
secretion [80]. Increased Substance P is also found in
the plasma of chronic cough sufferers [81].
Bradykinin
Itch Application of bradykinin to the skin evokes feel-
ings of weak itch and pain in healthy skin. However,
pruritic inflammation can change the effect of bradyki-
nin. If bradykinin is applied to itchy inflamed skin, like
lesions in AD patients, much more intense itch is felt.
Itch evoked by bradykinin is histamine-independent
[72]. When inflammation is induced by complete
freunds adjuvant (CFA), subsequent application of
bradykinin causes robust scratching. This behavior is
mediated by the kinin B1 receptor [82]. Both kinin
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This is proven by the reduced scratching of B1 and B2
knockout mice to different pruritic stimuli. B1 and B2
antagonists have similar effects [83]. Data suggests that
pruritic responses are mediated mostly by B2 receptors.
Antagonists of kinin (B1 and B2) receptors help reduce
itch from PAR2 agonists, implying that kinin receptors
are activated downstream from PAR2 and can mediate
protease evoked itch also [83]. It has been shown that pa-
tients taking angiotensin converting enzyme (ACE) inhibi-
tors for hypertension, occasionally suffer from pruritus as
a side effect [84]. ACE inhibitors lead to increased levels
of bradykinin, as ACE degrades bradykinin usually. The
increased levels of bradykinin are thought to cause the
pruritus, which is usually a precursor to a much more
dangerous side effect, angioedema [84,85].
Cough Bradykinin is endogenously produced, with air-
way inflammation causing an increase in levels [86].
Bradykinin can depolarize human, guinea pig and mouse
vagal afferents, activating C- and Aβ-fibers in the jugular
ganglion as well as nodose C-fibers [50,87]. In humans,
bradykinin causes cough and bronchoconstriction
[88,89]. Bradykinin also evokes cough in guinea pigs [16].
Activation is thought to occur through the B2 receptors
in the guinea pigs and humans but the B1 receptor is also
involved in mice, showing species differences [16,50,87].
B2 receptors are found in the vagal nodose ganglion of
rats and humans [90]. Bradykinin is also implicated in
sensitizing the cough reflex, enhancing cough response
to citric acid [78]. Patients taking ACE inhibitors (which
normally degrades bradykinin) often develop chronic
cough [91]. In fact, patients often stop taking the ACE in-
hibitor due to the chronic cough that develops.
Bradykinin’s tussive effects are tied to activation of
TRPV1 and TRPA1. Bradykinin’s activation of B2 receptors
works through the Gq/11 transducer, which results in PLC
and possible stimulation of TRPV1 [92,93]. Antagonists of
either channel alone partially inhibited in vivo and in vitro
responses of vagal neurons to bradykinin. Applying a
TRPV1 antagonist along with a TRPA1 antagonist com-
pletely prevented the effects of bradykinin [50].
Mast cell mediators
Mast cells are found in close contact to nerves, allowing
them to easily affect sensory perception [94]. Mast cells
play important roles in both itch and cough, especially
in chronic conditions. Scratching the skin of mice causes
significant mast cell degranulation within minutes [74].
In atopic dermatitis mouse models, increased levels of
degranulated mast cells are found [48]. In patients diag-
nosed with chronic nonproductive cough (CNPC),
bronchoalveolar lavage (BAL) showed increased num-
bers of inflammatory cells and airway inflammationwhen compared to controls [95]. Elevated levels of mast
cells were found in BAL samples in patients with
chronic cough [96]. Upon activation, mast cells de-
granulate and release biologically active mediators.
These mediators include histamine, serotonin, and pro-
teases [97]. We will discuss the roles of these mast cell
mediators in itch and cough below.
Histamine
Itch It is well established that introduction of histamine
to human skin causes itch [98,99]. Histamine also evokes
scratching in a dose-related manner in mice [100].
Spinothalamic neurons that respond to itch-evoking his-
tamine but not pain-evoking mustard oil were found in
the cat, implicating an itch specific pathway [101]. The
similarities and differences between itch and pain have
been discussed in other reviews and will not be covered
here [41].
Histamine is naturally produced by the body from the
amino acid histadine, with mast cells being one of the
main sources of histamine in the body [102,103]. There
are four subtypes of histamine receptors, H1-H4 [104].
The H1 receptor plays a starring role in evocation of itch
via histamine [105]. Antihistamines that block the H1
receptor have proven helpful in the treatment of uticaria
(hives), decreasing itching and reducing size of wheals
and flares [102]. Histamine receptors are GPCRs, acti-
vating an intracellular signaling network that results in
activation of ionotropic receptors, producing an action
potential. Therefore, histamine evokes currents only
when the H1 receptor is coexpressed with the ionotropic
TRPV1 receptor [44]. The H1 receptor is coupled with
Gq proteins and activates PLC [106]. Specifically H1 re-
ceptors are mediated through PLCβ3, which activates
TRPV1 [44,107]. Histamine is also shown to activate
TRPV1 via PLA2 [44]. Inhibiting PLA2 stops histamine-
induced Ca2+ influx in sensory neurons [108]. H4 recep-
tors are also implicated in itch. Histamine causes itching
in atopic dermatitis through activation of the H4 recep-
tor [102]. Patients with AD are also more sensitive to
histamine, showing increased responses in their skin le-
sions [109]. H4 agonists cause scratching upon injection
and H4 antagonists decrease itching and inflammatory
and pruritic symptoms in AD mouse models [110-112].
Cough Histamine also plays an important role in
modulating cough sensitivity. Histamine does not dir-
ectly cause cough as its application does not result in
action potentials in guinea pigs’ isolated vagal preps
[16,32]. In fact, application of histamine to vagal nod-
ose neurons only results in a small membrane
depolarization [113]. However, histamine does sensitize
vagal bronchopulmonary C-fibers’ response to capsaicin
and mechanical stimulation [114]. Antagonizing
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ric acid evoked cough [115]. Causing increased cough sen-
sitivity can lead to chronic cough and chronic cough
sufferers do have elevated levels of histamine in their spu-
tum and lungs [96,116]. Eosinophilic bronchitis, a disease
often causing chronic cough, increases levels of histamine
in patients’ sputum [117]. Human studies using ultrasonic-
ally nebulised distilled water (UNDW) to evoke cough
show reduced UNDW responses when loratadine, an H1
antagonist, is given to patients suffering from chronic dry
cough. This reduction implicates a role for histamine in
chronic cough conditions [118].
Serotonin
In rodents, a main source of serotonin is mast cells
[119]. While human mast cells can synthesize and se-
crete serotonin and may do so in inflammatory condi-
tions, this is not thought to be the primary source of
serotonin [120]. Serotonin can be found in platelets and
neuroepithelial bodies, which are innervated by vagal
sensory neurons, in the airway and thus still play a role
in cough evocation [121,122].
Itch Serotonin (5-HT) causes scratching when injected
into the faces of rats [123]. Topically applying serotonin
to the back of rats also results in scratching and activates
DRG neurons [124]. Mice also scratch in a dose-related
manner to 5HT [100]. In a dry skin chronic itch model,
a 5HT antagonist (ketanserin) significantly decreases
bouts of scratching in mice [125]. This implies a role for
5HT in chronic itch and patients suffering from eczema
and psoriasis do show increased expression of 5HT
[126,127]. However, in human studies, injection of 5HT
causes mixed feelings of itch and pain. The mixed sensa-
tions are felt through activation of a subset of cutaneous
C fibers [128]. Itching from intradermal 5HT injections
is thought to be partially mediated by the metabotropic
5-HT2 receptor as agonists of this receptor induce
scratching and antagonists reduce scratching [129]. The
ionotropic 5-HT3 receptor may also play a role in itch
as antagonists of the 5-HT3 receptor may be effective in
treatment of opioid-induced pruritus [130].
Cough Serotonin stimulates respiratory reflexes [131].
In dogs, phenylbiguanide, a 5HT receptor agonist, acti-
vates bronchial C-fibers [132]. Nodose ganglia C-fibers
respond to serotonin [93]. Specifically, serotonin acti-
vates the ionotropic serotonin receptor 5HT3 in rabbit
nodose ganglion neurons [133,134]. Triggering 5HT3 re-
ceptors leads to membrane depolarization of most small
diameter neurons in the vagal ganglia [135]. The guinea
pig also shows activation of the 5HT3 receptor on
intrapulmonary nodose C-fibers [93]. Interestingly, the
jugular ganglion C fibers in guinea pigs do not respondto 5HT [136]. However, 5HT does stimulate jugular gan-
glion C fibers in mice, possibly through a metabotropic
5HT receptor [137]. It is possible the metabotropic
5HT2A receptor might be involved, because in mouse
tracheal preps, serotonin causes tracheal muscle contrac-
tion via the 5HT2A receptor [119]. This contrasts with
activation of the nodose C fibers of mice, which is medi-
ated by the ionotropic 5HT3 receptor [137].
Proteases
Itch Endogenous serine proteases, including tryptase
and trypsin, cause itch by activation of the Protease
activated receptor (PAR) family. These GPCRs are acti-
vated when cleavage of the NH2 terminus of the PAR
receptor results in a tethered self-activating ligand
[138]. There are four members of the PAR family,
PAR1-4 [139]. PAR2 is involved in itch. PAR2 is a
seven-transmembrane GPCR that is proteolytically acti-
vated by trypsin and the agonist SLIGRL [140]. When
SLIGRL is injected into the skin of mice, robust
scratching is shown [141,142]. SLIGRL activation of
PAR2 releases PGE2 from keratinocytes, whose secre-
tion enhances scratching behavior [143]. DRG neurons
show PAR2 cells that coexpress with Substance P and
CGRP. When mast cells release tryptase, it activates
PAR2. PAR2 activation results in release of the
coexpressed neuropeptides, causing inflammation [144].
This activation cascade is thought to play a role in
trypsin induced scratching as well. Trypsin activates
PAR2 on mast cells, which results in release of SP and
CGRP and scratching. Data supports this by showing
depletion of mast cells prevented trypsin induced
scratching [145]. In chronic itch conditions such as
atopic dermatitis, increased expression of PAR2 was
found on primary afferent sensory nerves as well as in-
creased levels of tryptase [146]. Dry skin mouse
models exhibited sensitization to PAR2 agonists and a
PAR2 antibody helped reduce scratching [125]. PAR2
itch and neuron sensitization is thought to occur
through interaction with TRP channels, like TRPV1.
Deletion of TRPV1 or introduction of a TRPV1 antag-
onist prevents scratching from trypsin injection [145].
PAR2 has also been shown to coexpress with TRPV4 and
TRPA1 [147,148]. PAR2 pathways are histamine inde-
pendent because antihistamines did not help reduce itch
in atopic dermatitis or mice injected with SLIGRL
[141,146]. PAR4 has also been shown to elicit scratching
in mice upon activation [100]. PAR2 and PAR4 work
through the Gq protein and Ca
2+ signaling [27]. The ac-
tive component in cowhage, mucunain, has been shown
to be a ligand for PAR4 in addition to PAR2 [149].
Cough Proteases and their receptors also play a role in
cough and airway inflammation. In vagally innervated
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been shown to activate bronchopulmonary C-fibers by
activating PAR1 [30]. PAR2 has been implicated in air-
way inflammation also. PAR2 can be found in the airway
epithelial cells and smooth muscle of guinea pigs and
PAR2 agonists can cause bronchoconstriction [150].
Airway hyperactivity to inhaled stimulants was de-
creased in PAR2 knockout mice and increased in mice
overexpressing PAR2 when compared to wildtype con-
trols [151]. Patients suffering from bronchitis were
found to have increased expression of PAR2 [152].
This finding is supported by the knowledge that muco-
sal inflammation, a symptom of bronchitis, causes an
upregulation of PAR2 in the airway epithelium; as was
found in the skin in reference to itch, activation of
PAR2 by mast cell tryptase causes release of PGE2 in
the airway [153]. Inhalation of PGE2 has been shown
to cause cough in vivo and to sensitize the pulmonary
C fiber cough reflex [89,154].
Activation of PAR2 does not evoke cough directly as
data shows PAR2 agonist trypsin does not cause action
potentials in C-fibers innervating the trachea or bronchi
[155]. Activating PAR2 leads to PGE2 release though,
which has been shown to cause cough in vivo. Also
PAR2 plays a role in potentiating cough by sensitizing
cough evoked by TRPV1 stimulation [156]. PAR2 was
shown to coexpress with TRPV1 and sensitize the re-
ceptor through phosphorylation by the protein kinase
C pathway [156,157].
Doubt on PAR2’s role in itch was recently shown in a
2011 paper by Liu et al. It was shown that the PAR2
agonist SLIGRL activates a member of the Mrgpr family,
MrgprC11 and it is through the activation of this recep-
tor, that SLIGRL evokes itch [158]. This study also sug-
gested that trypsin induced itch did not act through
PAR2 or MrgprC11. Rather trypsin could act through
another PAR or an unknown subset of fibers. This
broadening of our knowledge of itch reminds us that
cough could be very similar. While PAR2 itself does not
seem to activate C fibers and induce cough, an unknown
subset of C fibers could be activated by the PAR2 ago-
nists, similar to the activation of MrgprC11 by SLIGRL.
Gastrin-releasing peptide receptor
Recently, evidence for itch specific neurons called
gastrin-releasing peptide receptor (GRPR) has been pub-
lished. The discovery of the pruritic role of these neu-
rons has opened new paths of discovery. With the idea
of itch and cough being similar in many respects, it
would be remiss of us not to compare the role of GRPR
in both conditions.
Itch Gastrin-releasing peptide (GRP) is the mammalian
homologue of the amphibian neuropeptide bombesin.GRP was found on peptidergic unmyelinated small to
medium sized DRG neurons with 80% of GRP+ neurons
also expressing TRVP1 receptors [142]. In GRPR knock-
out mice, scratching from histamine, SLIGRL and
chloroquine induced itch was reduced [142]. GRPRs are
found in lamina I of the dorsal horn and when an GRPR
agonist was injected intrathecally, bypassing peripheral
activation of the skin, scratching was exhibited,
supporting the idea of GRPR cells being itch specific
[142]. When GRPR spinothalamic cells were ablated
using bombesin-saporin, reduction of scratching from
pruritogenic (both histamine-dependent and histamine-
independent) stimulation was practically extinguished
[159]. This included scratching induced by 5HT and
compound 48/80, a mast cell degranulator.Cough Bombesin induces bronchoconstriction in guinea
pigs airways, an effect that is absent if the trachea or
bronchi was stripped of its epithelium [66]. In rats, GRP
and bombesin exposure cause an increase in rapid, shal-
low breathing characteristic of activation of C-fibers. In
fact, GRP and bombesin increase the pulmonary
chemoreflex response to capsaicin. This potentiation is
blocked when pulmonary C-fiber conduction is not
allowed [160]. All three types of bombesin-like peptide
receptors are found in human lung tissue, specifically in
human bronchial epithelial (HBE) cells [161]. Having the
receptors located in the airway epithelium, close to where
C-fibers terminate, implies that GRP could play a regula-
tory role on the C-fibers involvement in the cough reflex.Conclusions and future directions
The field of itch research has only started to be ex-
plored, with much expansion seen over the last couple
of years. There are still many challenges that need to be
overcome in the itch field. Recently, many novel itch re-
ceptors and pruritogens have been identified, however,
our knowledge on how they function or mis-function
during chronic itch conditions is still limited. Is there a
common downstream factor which is required for most,
if not all, itch signaling pathways? If such a factor is dis-
covered, it will most likely be found using animal stud-
ies. Therefore as our knowledge of itch expands, these
findings should also be validated in human studies. This
will require extensive collaboration between basic re-
searchers and clinicians, eg dermatologists, which can be
logistically difficult. Another challenge is that while most
major pharmaceutical companies are developing anti-
pain drugs, many companies do not realize that chronic
itch is a major clinical problem. Without industrial col-
laboration, it is difficult for basic research laboratories to
conduct large scale screens to identify itch blockers.
Pharmaceutical companies need to be convinced that
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market values.
As our anatomical knowledge of itch grows, it is obvi-
ous that the sensory Aδ- and, more importantly, C-fibers
play a pivotal role in itch perception. Tied closely to acti-
vation of these sensory fibers is neurogenic inflammation,
which involves release of inflammatory agents like SP
and bradykinin as well as products of mast cells, all
which result in itch, flares, wheals, and can easily become
chronic conditions. All of these individual factors also
play roles in cough and the similarities between itch and
cough in sensing irritants from environment can be seen.
Cough has an additional factor to incorporate though,
movement. While the end result of itch is scratching, the
muscles and joints being used to scratch are not receiv-
ing signals directly from the itching skin. With cough,
smooth muscle movement is incorporated into the actual
cough reflex in order to move the irritant or blockage up
the airway and out. It is this additional motility aspect
that could result in more specialized involvement of
myelinated fibers in cough, a specialization not needed in
itch. Chronic cough is one of the most common reasons
to visit the doctor and like chronic itch, can quickly be-
come detrimental to quality of life [162]. Realizing the
similarities between itch and cough can lead to new ideas
and even perhaps, new ways to apply existing medica-
tions to new conditions.
Clinically, anti-histamines are often prescribed and
have been shown to help with itch and cough. However,
by no means do anti-histamines help with all conditions.
This indicates a real need to discover the histamine-
independent pathways involved. Progress has been made
recently in histamine-independent itch research with the
discovery of the family of Mrgprs.
Mrgpr genes encode a family of orphan G protein-
coupled receptors (GPCRs) consisting of more than
50 members in the mouse genome [2,163,164]. The
expression of many Mrgprs, including MrgprA3 and
MrgprC11, is found in subsets of small-diameter sen-
sory neurons in DRG and trigeminal ganglia
[2,163,164]. The human MrgprXs is also selectively
expressed in DRG neurons [165]. The specific expres-
sion pattern of Mrgprs in primary sensory neurons in-
dicates that these receptors play essential roles in
sensation such as pain and itch. Mrgprs should be ex-
amined for contributions to cough. Besides the DRG,
MrgprA3 and MrgprC11 are also expressed in the
mouse nodose/vagus ganglion, which innervates the
airway. With the discovery of specific ligands for
MrgprX1 and MrgprC11, such as BAM8-22, the tus-
sive role of Mrgprs can be quickly explored. For ex-
ample, β-alanine activates MrgprD+ neurons which
are histamine insensitive [166]. It would be interesting
to know whether application of Mrgpr agonists such asβ-alanine can cause cough. If so, are Mrgpr expression
levels increased under chronic cough conditions?
Realizing the similarities between itch and cough
might result in the expansion of the repertoire of tussive
agents. Or working in the other direction, increase the
number of pruritogens, which is very useful for chemical
probing. Expanding the knowledge of cough by realizing
the parallels and similarities to itch can lead to new ther-
apies and treatments for both. This increase of know-
ledge and theory could eventually lead to enhancements
in treatments of chronic itch and cough that could help
the millions suffering every day.
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